‘Favourable-risk’ cytogenetic abnormalities include Acute Myeloid Leukaemia- Eight Twenty-Two (AML-ETO), also known as RUNX1 Translocation Partner 1 (RUNX1T1), Pro Myelocytic Leukaemia- Retinoic Acid Receptor alpha (PML-RARA) and Nucleophosmin 1 (NPM1) mutations [12,13]. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.